NeuroCME
EXPERT VIDEOCME

Shutting Down MS: New Insights on Induction, Escalation, Oral Agents, and Monitoring

Author(s)/Faculty: Patricia K. Coyle, MD, FAAN, FANA; Bruce A. Cohen, MD, FAAN, FANA, FACP; Clyde E. Markowitz, MD
Release Date: 3/28/2018Expiration Date: 3/27/2019
Credit Type: CMENumber of Credits: 1
Content Type: VideoProvider:
Multiple sclerosis (MS) is a chronic inflammatory, demyelinating, and neurodegenerative disorder of the central nervous system, with a variable disease course. Approximately 85% of patients are diagnosed with relapsing–remitting MS (RRMS); of these, 50% to 60% progress after 10 to 20 years to secondary progressive MS, which is characterized by continuously worsening disability, without periods of remission. Treatment decisions for patients with RRMS are increasingly challenging as new agents rapidly emerge in the therapeutic landscape. Two different strategies for treatment have emerged—an “escalation” paradigm in which therapies with the least potential for toxicities are first utilized and an alternative “induction” approach in which more powerful treatments are initiated. In this CME activity, experts will evaluate these 2 management strategies, including the efficacy and safety data for oral agents used in the treatment of patients with RRMS. Monitoring patients for response, safety, tolerability, and adherence to prescribed RRMS therapies will also be reviewed.